Alphatec Holdings, Inc. (NASDAQ:ATEC) Shares Sold by King Luther Capital Management Corp

King Luther Capital Management Corp lessened its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 27.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 771,277 shares of the medical technology company’s stock after selling 291,443 shares during the period. King Luther Capital Management Corp’s holdings in Alphatec were worth $4,288,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Jennison Associates LLC acquired a new stake in shares of Alphatec during the third quarter valued at $686,000. Wrapmanager Inc. lifted its holdings in Alphatec by 9.5% in the 3rd quarter. Wrapmanager Inc. now owns 38,399 shares of the medical technology company’s stock valued at $213,000 after purchasing an additional 3,325 shares in the last quarter. Royce & Associates LP boosted its stake in shares of Alphatec by 15.9% during the 3rd quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock worth $6,740,000 after purchasing an additional 165,954 shares during the last quarter. Zions Bancorporation N.A. grew its holdings in shares of Alphatec by 108.2% during the third quarter. Zions Bancorporation N.A. now owns 173,180 shares of the medical technology company’s stock worth $963,000 after buying an additional 89,992 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Alphatec in the third quarter valued at approximately $431,000. 66.35% of the stock is owned by hedge funds and other institutional investors.

Alphatec Stock Performance

Alphatec stock opened at $10.06 on Friday. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $17.34. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -7.97 and a beta of 1.31. The stock’s 50-day moving average is $6.62 and its 200-day moving average is $8.30.

Analyst Ratings Changes

ATEC has been the subject of several recent analyst reports. Wells Fargo & Company lowered their target price on shares of Alphatec from $26.00 to $19.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Stifel Nicolaus dropped their target price on Alphatec from $19.00 to $16.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Barclays raised their price target on Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Tuesday. Lake Street Capital dropped their price objective on shares of Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Finally, Morgan Stanley cut shares of Alphatec from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.11.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.